About admnaturis

This author has not yet filled in any details.
So far admnaturis has created 45 blog entries.

Bionaturis Signs Binding Agreement With ADL For Integration Operation

• Bionaturis and ADL Biopharma will create a European biotechnological benchmark.
• The integration operation is subject to the pertinent approvals.
• After the integration, a capital increase is planned to enhance the free-float, the liquidity of the shares and to finance the growth of the integrated company
• Black Toro Capital, the fully owners of ADL Biopharma, will control 85% of the resulting company.

Bionaturis (ticker BNT) have just signed a binding integration agreement with ADL Biopharma, a company specialized in industrial bioprocessing of fermentation-based products with applications in human and animal health.This integration agreement aims to build-up a European leader in red biotechnology, focused mainly on the development and commercialization of high-value fermentation-based bioproducts.Bionaturis will add its capacity to develop premium products and its position as a reference partner of the One Health concept, and ADL will contribute with one of the biggest fermentation sites in Europe and with a broad customer portfolio. The integration will produce many synergies for both companies, highlighting the level of complementarity of their customers and products. The resulting company will offer a broader spectrum of products and services, covering different features and needs of the steady growing human and animal health sectors.

Pilar de la Huerta, CEO of ADL Biopharma, has stated: “Bionaturis innovation capacity along with the industrial capacity of ADL will expand quickly our products and market opportunities, enhancing our growth significantly, and positioning the integrated company as a leader in Southern Europe in the development and production of fermentation bioproducts for human and animal applications”.

For Victor Infante, CEO of Bionaturis Group, as a reference partner in the One Health concept the operation “will increase our customer base, expand the industrial production capacity of our premium products and will enhance our innovation in the fields of human and animal health. The new structure will help us optimize the […]

December 4th, 2017|Blog english, Hechos Relevantes|Comments Off on Bionaturis Signs Binding Agreement With ADL For Integration Operation

Bionaturis reports a supply contract worth of €4,77 million/year

· The animal health division of Bionaturis Group has signed a license agreement for the supply and distribution of non-prescription products for livestock with minimum annual orders worth of € 4.77 million

· The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock

· The signing of this contract joins the uptrend of significant organic growth that every divisions of the group is performing

Jerez de la Frontera, November 16, 2017.


Bionaturis Group has reported that its animal health division has signed a license agreement for the exclusive registration and commercialization of non-prescription products for food production animals (FPAs) with an international client of regional scope. Under the license agreement, Bionaturis will supply the products and technical assistance, while the client will be in charge of importing, distributing and selling them, as well as obtaining the marketing authorization, whose ownership will be shared. The supply agreement has an initial term of three years with automatic renewal of one-year periods and a minimum annual order commitment of €4.77 million euros, once the marketing authorization has been obtained, estimated for the second quarter of 2018.

The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock farms, one of the cornerstones of the One Health concept “one world, one health”, that summarizes an idea that had been known for more than a century; that human health and animal health are interdependent and bound to the health of the ecosystems in which they exist. According to the OIE – World Organization for Animal Health, 60% of known human infectious diseases are zoonotic (domestic or wild animals), as well as 75% of emerging human diseases have animal […]

November 16th, 2017|Blog english|Comments Off on Bionaturis reports a supply contract worth of €4,77 million/year

Bionaturis will show its value in BioEurope, Berlín.

From November 6 to 8th, Bionaturis Group will take part in BioEurope 2017, to be held in Berlin this edition, to present its rich portfolio of premium products and services.

2176 biotechnological and pharmaceutical companies come together in this event from November 6th to November 8th, 2017. In total they will put in negotiation on 5108 biotechnological assets in the meetings already agreed between the assistants during two months previous to the event.

2176 biotechnological and pharmaceutical companies will come together in this event where 5108 biotechnological assets will be put in negotiations during the pre-scheduled one to one meetings.

All the business divisions of Bionaturis Group will be represented in this edition.  Juan Jose Infante, Chief of biological developments as part of the Animal Health division, Andoni Cruz, representing the CRO services and Miriam Bastida, showcasing the bioprocessing optimization tools of the CDMO division.

As a partner of choice to bring premium products to the market place, Dr. Infante will meet the world leaders representatives in animal health to follow up the joint on-going initiatives and to open-up new licensing opportunities for co-development.

After the successful participation in BioEurope Spring and having already exceeded the sales figure of the whole previous year, Biobide (CRO division) will be in Berlin in order to strength its relationship with its pharmaceutical and biotechnological network, to set new collaborations, as well as to showcase its new services in zebrafish, being an international reference in this field.

Miriam Bastida will update attendees about the latest of Splittera and Zera, within the CDMO division of bioprocesses, specifically designed to optimize the developments of biological drugs, which presents a global expected market figure worth of 236 billion dollars by 2019.

For more information, visit the official web here.



November 6th, 2017|Blog english|Comments Off on Bionaturis will show its value in BioEurope, Berlín.

Splittera patent of Bionaturis Group granted in China and Japan

Bionaturis Group has received notification of the approval of two patents of the same family by the Chinese (SIPO) and Japanese (JPO) offices, conferring protection in both territories, two of the most important markets worldwide.The patent entitled “Split inteins and uses thereof”, contributes to the protection of the Splittera system, joining to the protection already conferred in the main European markets.

These patents are of special relevance for Bionaturis group since Splittera is subject of a worldwide exclusive licensing agreement with a top leading multinational company, for its commercialization in the industrial purification of biological products. The agreement contemplates upfront, milestone-payments and royalties for sales. This agreement is a proof of principle of the usefulness and added value of Splittera for the biopharmaceutical sector, which presents a global expected market figure worth of 236 billion dollars by 2019.

Splittera is part of the technological portfolio of the CDMO division of the biotechnological group, provided by ZIP Solutions, a specialist in bioprocesses for the production of peptides and recombinant proteins at industrial scale.

Please, click here to read the Relevant Information (only in Spanish)About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).


November 2nd, 2017|Blog english|Comments Off on Splittera patent of Bionaturis Group granted in China and Japan

Bionaturis announces H1-2017 and YTD results

Executive Summary

Reports Revenue YTD of €1.28 million, expecting more than 60% growth for the full year 2017
Reports EBITDA YTD of €355 k, +802 thousand euros compared to the full year 2016
Reports the executions of an exclusive license agreement for the development, registration, manufacturing, and commercialization of BNT005 in Argentina and Paraguay.
Reports the signing of an Evaluation and Licensing agreement with exclusive worldwide license rights (except in Argentina and Paraguay) for the development, registration and commercialization of BNT005 with a top leading company in the sector
Reports ZIP patents granted in USA, EUROPE and JAPAN
Reports reaching an E&O agreement with a global leader for the exclusive development, registration and marketing of a probiotic for oral application, indicated to improve oral health in companion animals
Reports the signing by Biobide of new relevant contracts with three leading companies in the agrochemical and biomedicine sectors, for a cumulative amount worth of USD 1.39 million
Reports BNT005 patent granted in CHINA.


Click here to see the official document. (only spanish)


October 27th, 2017|Blog english|Comments Off on Bionaturis announces H1-2017 and YTD results

Biobide signs new contracts worth of USD 1.39 million

Biobide -Bionaturis group- an international reference CRO on zebrafish, reports that it has signed new relevant contracts with three leading companies in the agrochemical and biomedicine sectors, for a cumulative amount worth of USD 1.39 million. Under the terms of these new contracts, Biobide will use its zebrafish platform for the optimization of the drug discovery process of the customers. Using this platform, Biobide´s customers can filter and early-detect the safety and efficacy profile of its leads, meaning a significant saving of time and costs.

These new relevant contracts are just another example of Biobide’s leadership position in the growing zebrafish sector. Customers like Roche, Servier, Sanofi, or NIH-NIEH endorse Biobide as an international reference CRO in zebrafish.

For the official disclosing Click here (Only in Spanish)

September 28th, 2017|Blog english|Comments Off on Biobide signs new contracts worth of USD 1.39 million

Bionaturis under the eyes of the investor: Miguel Cuevas

usHis Twitter’s account gives us some tracks on him….

” There is nothing more powerful than an idea which his time has come to him ”

But we are going to know him more…

-MIGUEL, define you in 140 characters.

With 30 years of age behind my back! I consider myself a humble and hard-working person, with the desire to learn day after day to be able to excel in everything what the life puts me ahead. Carried away of animals. I have a Siberian Husky that it is quite for me, and in addition, he ask me every day for a visceral canine Leshismaniasis vaccine.

-QUESTION: Now that we already know a bit more of you, tell us Miguel, how did you discover Bionaturis and what it is you turns out more attractive of this group?

For the year 2014 in full summit of Mab they spoke to me about two companies with a great future and one of them was Bionaturis. In them, I saw a promising business and a few incredible perspectives of future.

-QUESTION: What sparked your attention our your personal motivation to invest in this group?

The biotechnology, of which it had not even idea (I am of the IT world) and it woke my curiosity up. Can we create a vaccine from a butterfly?  Treat a dog? If gentlemen, we can treat a dog from a butterfly! Something off the hook! In this moment with 12 BNT in process of study and with the FlyLife technology in full summit. I thought: why not to invest my money in this company?

-QUESTION: Related to other advanced economies, Spain presents an abnormally low  number of investors of minority type which do you think about the principal motives and what measures you would put in going in […]

September 26th, 2017|Blog english|Comments Off on Bionaturis under the eyes of the investor: Miguel Cuevas

Bionaturis leishmaniasis vaccine patent granted in China

The State Intellectual Property Office (SIPO) of the People’s Republic of China has granted to Bionaturis and CSIC the patent entitled “Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the protein of leishmania infantum with specific immunodominant epitopes “ under the number CN 201280045285. This patent belongs to the original patent family that protects the use and application of the candidate BNT005 for the treatment and prevention of canine visceral leishmaniasis.

BNT005 is currently subject to an Evaluation and Option (E&O) agreement with an international sponsor for the exclusive worldwide license to register and commercialize this vaccine against canine leishmaniasis in all countries except Argentina and Paraguay.

At the same time, BNT005 is also subject to an exclusive license agreement for registration, development, manufacture and marketing with Biotandil for the Argentine and Paraguayan markets. Under the agreement, Bionaturis will receive 50% of the profits from the commercial exploitation of the vaccine within the territory.

For the official disclosing Click here (only in Spanish)

September 21st, 2017|Blog english|Comments Off on Bionaturis leishmaniasis vaccine patent granted in China

September Newsletter


EUROTOX conference, that takes place every year, is one of the most important European event in the toxicology area for Biobide.



The attendance to this conference was a great opportunity for Biobide to meet with clients and collaborators as well as to present the latest projects and investigations of the company within the toxicology field. During the posters session, Biobide presented the  poster in collaboration with Tecnun-University of Navarra, “In-silico platform based on bioinformatic and cheminformatic data to complement zebrafish embryo teratogenicity test”, which rose great interest and expectation among the attendees.

Moreover, Biobide’s participation as exhibitor received very positive feedback and allowed the company to stablish new relationships within the pharmaceutical, chemical and cosmetic sectors.

The next edition of EUROTOX will be held in Brussels in September 2018 and Biobide will be also present as worldwide zebrafish CRO leader.

September 20th, 2017|Blog english|Comments Off on September Newsletter

Biobide is involved in two events in Europe.

Biobide, part of Bionaturis Group and CRO of world reference specialized in the zebrafish alternative model, will take part in the following events in September.

*European Teratology Society (Monday 4th – 7th September 2017)

In this annual event will take part Maitane Ipiñazar (Business Development Manager) and Celia Quevedo (Study Director), who will present the poster titled “Toxicity profiling using a battery of assays in zebrafish embryos including teratogenicity, behaviour, cardiotoxicity, ototoxicity and hepatotoxicity”.

The Key sessions for ETS 2017 will include:

· Education Course: Hormones and Brain Development

· Pre-term births

· Safety Assessment of Herbal Drugs in Pregnancy

· Transplacental Exposure to Tumorigenic Agents

· IATA – Integrated Approaches to Testing and Assessment

· Satellite Workshop: Best Practices in interpreting developmental toxicity data


To register  you have to enter the official web of the event:



*EUROTOX (Bratislava, 10th -13th September).

Biobide’s delegates from the Business Development area, Maitane Ipiñazar and Ane Altuna, will be the ones attending the event this year, on this occasion as exhibitors with the booth number 32.Moreover, Biobide’s Business Development Manager will present their latest poster the 11th of September (P-03-03-02): “In-silico platform based on bioinformatic and chemoinformatic data to complement zebrafish embryo teratogenicity test.”

The Scientific Programme Committee is preparing an exciting programme with over 30 symposia and workshops that will highlight the novel findings in the field of toxicology. Four Poster Sessions and five Continuing Education Courses will offer a wide range of opportunities to enhance and enrich the professional experience.

To register  you have to enter the official web of the event:

To arrange a meeting with Biobide in any of these two international events, please write an email to

You can also visit our web:

August 30th, 2017|Blog english|Comments Off on Biobide is involved in two events in Europe.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.